Idiopathic Inflammatory Myopathies
3
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
150%
Cell Therapy
150%
+ 1 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
SandozRapcabtagene autoleucel
Prevail TherapeuticsBaricitinib
Kyverna TherapeuticsKYV-101
Clinical Trials (3)
Total enrollment: 60 patients across 3 trials
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
Start: Dec 2024Est. completion: Nov 203221 patients
Phase 2Active Not Recruiting
JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM
Start: Oct 2021Est. completion: Sep 202315 patients
Phase 2Completed
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
Start: Aug 2024Est. completion: Feb 202724 patients
Phase 1Active Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.